hPD-1/hPD-L1

Fig1. The expression of human PD-1 and PD-L1 in double humanized PD-1&PD-L1 mice was confirmed by FACS.

Fig 2.Frequency of leukocyte and myeloid subpopulations in the spleen by flow cytometry

Spleen was collected from WT C57BL/6 mice and HO hPD-1/hPD-L1 mice (8-week-old, female, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the spleen. Bar indicated expressed as mean ± SEM.

Abbr.  HO, homozygous; WT, wild type.

Fig 3.Frequency of leukocyte and myeloid subpopulations in the blood by flow cytometry

Blood was collected from WT C57BL/6 mice and HO hPD-1/hPD-L1 mice (8-week-old, female, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the blood. Bar indicated expressed as mean ± SEM.

Abbr.  HO, homozygous; WT, wild type.

Efficacy study

Fig4. In vivo validation of double humanized PD-1&PD-L1 mice. Double humanized mice were inoculated with MC38 cells, and randomly assigned to different groups (n=8) when the tumor grew to a volume of 100 mm3. A combinatorial treatment of anti-PD-L1 and anti-PD-1 demonstrated a noticeable efficacy improvement compared to the same dose of single agent (top) without affecting the animal body weight (Bottom).